arGEN-X N.V., a clinical-stage biopharmaceutical company, focuses on creating and developing therapeutic antibodies for the treatment of cancer and autoimmune diseases. The company was founded in 2008 and is based in Breda, Netherlands.
ARGX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Argenx Se with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Argenx Se ranked in the 84th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Argenx Se ended up being:
The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately only 1.85% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Argenx Se's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -1,274.91. This coverage rate is greater than that of just 0.38% of stocks we're observing for the purpose of forecasting via discounted cash flows.
As a business, Argenx Se experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Argenx Se? See HCA, NVCR, NHC, FVE, and VMD.
Thinly traded argenx SE (ARGX) perks up 1% premarket on light volume on the heels of Johnson & Johnson's (JNJ) $6.5B takeout of Momenta Pharmaceuticals (MNTA).The Belgian biotech's antibody engineering technology is similar to Momenta's, both involving the Fc region where antibodies modulate other cells in the immune system.In May, argenx reported...
* Biologics License Application for efgartigimod in generalized myasthenia gravis on track to be submitted to U.S. Food and Drug Administration by end of year * Full data from ADAPT trial to be presented at upcoming medical meeting in 2020 * Cusatuzumab development strategy aligned with evolving AML treatment landscape to focus on combination with venetoclax and azacitidine * €1.9 billion in cash and cash equivalents and current financial assets strongly support commercial launch preparation of efgartigimod * Management to host conference call today at 2:30 pm CEST (8:30 am ET) July 30, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disease...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]